TCRT has been on continuous publication since 2002. It is covered currently by all the major data systems such as Medline, PubMed, Web of Science, Thomson's ISI and SCI and Scopus.
The 2012 Impact factor for TCRT is 1.943
Cancer Cells Ablation with Irreversible Electroporation (p. 699-706)
In this study we perform in vitro irreversible electroporation (IRE) experiments with human hepatocarcinoma cells (HepG2) to investigate IRE as a new technique for undesirable tissue ablation. Irreversible electroporation (IRE) is the irreversible permeabilization of the cell membrane through the application of microsecond through millisecond electrical pulses. Until now IRE was studied only as an undesirable condition during the use of reversible electroporation in gene therapy and electrochemotherapy. There was a possibility that the IRE ablation domain is mostly superimposed on the electrical pulses induced Joule heating thermal ablation domain. This study demonstrates that there is a real and substantial domain of electrical parameters for IRE ablation of cancer that is distinct from the thermal domain and which results in complete cancer cell ablation. Experiments show that the application of 1500 V/cm in three sets of ten pulses of 300 microseconds each can produce complete cancer cell ablation. We also find that the use of multiple pulses appears to be more effective for cancer cell ablation than the application of the same energy in one single pulse.
Key words: Hepatic cancer; Irreversible electroporation; and Thermal effects.
TCRT December 2005
No. 6 (p 583-712)
Featured ImageCollagenhydroxyapatite/Cisplatin Drug Delivery Systems for Locoregional Treatment of BoneCancer. Andronescu et al., Technol Cancer Res Treat 12(4), 275-284 (2013). www.tcrt.org/product-p18037.html